Breast Cancer Clinical Trial
Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)
Summary
The primary objective of this study is to compare the safety of 100 mg carboplatin administered intraductally once on Day 1 or twice on Days 1 and 15 in women with ductal carcinoma in situ (DCIS) undergoing surgical management 2 to 4 weeks following the Day 15 intraductal infusion. Secondary objectives are to characterize the biologic and clinical effects with respect to: pharmacokinetics, extent of disease on MRI and mammogram, histopathological assessment of DCIS, and biomarker measurement of Ki-67, TUNEL and G-actin.
Full Description
This is a randomized, 3-arm, saline-controlled study involving women undergoing surgical management of DCIS. Forty-five (45) women who have been diagnosed with DCIS by core biopsy will receive intraductal administration of either carboplatin or normal saline (NS) into the DCIS-involved breast duct. Thirty (30) patients (i.e., 15 patients per arm) will receive two intraductal infusions of either 100 mg of carboplatin or NS on Days 1 and 15. Fifteen (15) patients will receive an intraductal infusion of 100 mg carboplatin on Day 1 and an intraductal infusion of NS on Day 15. Patients will undergo surgical resection 2 to 4 weeks following the Day 15 intraductal infusion (i.e. 4 to 6 weeks from diagnosis).
The effect of carboplatin on DCIS in the pre-treatment core biopsy specimen and the resection specimen will be assessed. Venous blood samples will be collected for carboplatin PK analysis pre-dose and at 30 minutes, 1, 2, 4, and 8 hours following intraductal infusions on Days 1 and 15.
Eligibility Criteria
Inclusion Criteria:
Female
18 years of age or older
Scheduled to undergo surgical resection in 2 weeks or longer
Pathological diagnosis of DCIS requiring surgical resection
DCIS diagnosed with core biopsy
Mammogram within 6 weeks of diagnosis
Adequate organ function as defined by the following criteria:
Absolute neutrophil count (ANC) ≥ 1500/μl, Platelets ≥ 140,000/μl,Hemoglobin ≥ 12.0 g/dl, Creatinine < 2.0 mg/dl
- Able to sign informed consent
Exclusion Criteria:
Current diagnosis of invasive or inflammatory breast carcinoma
DCIS with microinvasion on histology on core needle biopsy
Palpable mass
Mass on mammography
Concurrent anti-cancer therapy
Prior exposure to carboplatin (related to current or past diagnosis)
Prior radiation to the breast or chest wall
Prior areolar or breast surgery which interrupts communication of the ductal systems with the nipple
Presence of breast implants
Presence of ulcerating or fungal skin lesions or infection of the breasts
Pregnant or lactating
Impaired cardiac function or history of cardiac problems
Poor nutritional state (as determined by clinician)
Presence of serious infection
Scheduled for intraoperative radiation of breast or chest wall
Allergies to lidocaine or marcaine
Allergies to imaging dyes
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 2 Locations for this study
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.